For: | Shih CA, Chen WC. Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy. World J Clin Cases 2021; 9(21): 5769-5781 [PMID: 34368296 DOI: 10.12998/wjcc.v9.i21.5769] |
---|---|
URL: | https://www.wjgnet.com/2307-8960/full/v9/i21/5769.htm |
Number | Citing Articles |
1 |
Jia-Rui Zheng, Zi-Long Wang, Bo Feng. Hepatitis B functional cure and immune response. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.1075916
|
2 |
Sara Lacerda Pereira, Raquel Duro, António Sarmento. Late Hepatitis B reactivation after treatment with rituximab. IDCases 2022; 27: e01393 doi: 10.1016/j.idcr.2022.e01393
|
3 |
Caterina Sagnelli, Antonello Sica, Massimiliano Creta, Alessandra Borsetti, Massimo Ciccozzi, Evangelista Sagnelli. Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19. Pathogens 2022; 11(5): 567 doi: 10.3390/pathogens11050567
|
4 |
Serena Zaltron, Anna Cambianica, Marco Di Gregorio, Cosimo Colangelo, Samuele Storti, Giorgio Tiecco, Francesco Castelli, Eugenia Quiros-Roldan. Case report: An occult hepatitis B virus infection reactivation in an HIV/HCV coinfected patient during an immune reconstitution inflammatory syndrome. Frontiers in Cellular and Infection Microbiology 2023; 13 doi: 10.3389/fcimb.2023.1143346
|
5 |
Tânia Lourenço, Nuno Vale. Entecavir: A Review and Considerations for Its Application in Oncology. Pharmaceuticals 2023; 16(11): 1603 doi: 10.3390/ph16111603
|
6 |
Chunyan Yuan, Jing Peng, Renxiang Xia, Jian He, Tianji Qiu, Yunqing Yao. Reactivation of Occult Hepatitis B Virus Infection During Long-Term Entecavir Antiviral Therapy. Frontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.865124
|
7 |
Adeniyi Abraham Adesola, Matei-Alexandru Cozma, Yong-Feng Chen, Bahadar Singh Srichawla, Mihnea-Alexandru Găman. Risk of hepatitis B reactivation in patients with myeloproliferative neoplasms treated with ruxolitinib. World Journal of Hepatology 2023; 15(11): 1188-1195 doi: 10.4254/wjh.v15.i11.1188
Abstract(211) |
Core Tip(161) |
Full Article(HTML)(1004)
|
Full Article with Cover (PDF)-1278K(41)
|
Full Article (Word)-185K(25)
|
Audio-1002K(3)
|
Peer-Review Report-190K(22)
|
Answering Reviewers-264K(19)
|
Full Article (PDF)-482K(73)
|
Full Article (XML)-81K(33)
|
Times Cited (0)
|
Total Visits (2594)
|
Open
|
8 |
Jiajia Hu, Jie Zhao, Chunyan Wang, Mei Jia, Ming Su, Shanshan Li. Epstein–Barr virus reactivation correlates with worse outcomes for patients exposed to hepatitis B virus after haploidentical hematopoietic stem cell transplantation. Annals of Hematology 2023; 102(12): 3593 doi: 10.1007/s00277-023-05492-z
|
9 |
Shahrzad Shoraka, Seyed Reza Mohebbi, Seyed Masoud Hosseini, Amir Ghaemi, Mohammad Reza Zali. SARS-CoV-2 and chronic hepatitis B: Focusing on the possible consequences of co-infection. Journal of Clinical Virology Plus 2023; 3(4): 100167 doi: 10.1016/j.jcvp.2023.100167
|
10 |
Zahra Dossaji, Lubaba Haque, Adam Khattak, Mark Hsu, Robert Gish. A Review of Hepatitis B Reactivation Risk on Immunosuppressants with a Focus on Newer Immunomodulators. Current Hepatology Reports 2024; doi: 10.1007/s11901-024-00662-7
|